Relmada Therapeutics (RLMD), a clinical-stage pharma company, has seen a 440% increase in shares since August. Despite technical strength, RLMD lacks revenue, faces pipeline setbacks, and is rated “Hold” on Wall Street. Valued at $141 million, RLMD has NDV-01 in its pipeline for non-muscle invasive bladder cancer. The stock hit a 52-week high of $5.21 and has a 100% “Buy” opinion from Barchart. Analysts rate it as a “Hold” and individual investors have mixed opinions. With no revenue projected, it’s essential to conduct thorough due diligence before investing in RLMD.

Read more at Barchart: This Stock Is Up 704% in 2025 But Has No Products to Its Name